By Ben Glickman

HilleVax on Thursday named Sean McLoughlin as the vaccine developer's next operating chief.

The Boston-based biopharmaceutical company said that co-founder and current COO Aditya Kohli will become chief business officer as part of a planned transition.

McLoughlin, 52, recently served as global vaccine commercialization lead, RSV at GSK. He has held various roles at GSK over 25 years with the company.

McLoughlin will receive an annual base salary of $450,000, with an annual target bonus of 45% of his salary and a sign-on bonus of $200,000.

Write to Ben Glickman at ben.glickman@wsj.com

(END) Dow Jones Newswires

January 18, 2024 07:34 ET (12:34 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Grafico Azioni HilleVax (NASDAQ:HLVX)
Storico
Da Dic 2024 a Gen 2025 Clicca qui per i Grafici di HilleVax
Grafico Azioni HilleVax (NASDAQ:HLVX)
Storico
Da Gen 2024 a Gen 2025 Clicca qui per i Grafici di HilleVax